Letters to the Editors

Systemic sclerosis and COVID-19: what’s new in the literature

Sir,
During the current pandemic, identifying patients most at risk for COVID-19 is crucial. Older age and underlying health disorders have been identified as risk factors for severe disease (1). Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterised by inflammation and fibrosis of the skin and internal organs. Infections are more common among SSc patients, especially in those with respiratory and oesophageal disease, and contribute to morbidity and excess mortality (2). Moreover, immunosuppressive medications increase vulnerability of the patients so that, if infected, may develop a more severe and prolonged disease course (2). However, little is known about the clinical course of COVID-19 in patients with systemic sclerosis (SSc).

We conducted a systematic literature review on Medline, Embase, and Web of Science (WoS) from December 1st 2019 up to and including June 22nd 2020. All types of papers reporting cases of SSc infected with SARS-CoV-2 were included. The literature search resulted in 350 hits, after duplicates were eliminated. Following the screening of titles and abstracts, seven articles were found to be relevant. An eighth relevant study was retrieved by screening references of included papers, and added manually.

The eligible articles include 2 case reports (3, 4), one case series (5), two retrospective studies (6, 7), two surveys (8, 9), and one paper summarising the findings of a large registry (10). A total of 25 SSc patients were identified. Gender was provided for 9 patients of which 7 (78%) were female. Among the same 9 patients, age was listed, with a median of 65±16.5 years (range 32-84) (Table I). COVID-19 infection was severe in 7 of 9 cases providing information on disease course, with 3 recorded deaths. Among the 3 patients with interstitial lung disease, one developed a mild disease, one required intensive care unit level care and one died. Treatment at diagnosis (available for 7) included rituximab (n=4, severe), tocilizumab (n=1, mild), mycophenolate mofetil (n=1, severe), and methylprednisolone (n=1, severe).

Our study shows a significant heterogeneity in the information provided about SSc and the clinical course of COVID-19. Symptoms at onset of SARS-CoV-2 infection in SSc are in line with those described in the general population. HRCT features seem to

Table I. Included studies with features of underlying systemic sclerosis and COVID-19 clinical course.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Country</th>
<th>Population</th>
<th>No. of SSc</th>
<th>Age</th>
<th>Sex</th>
<th>SSc-related Rx</th>
<th>Subset</th>
<th>Auto-Abs</th>
<th>Extra-skin organ involvement</th>
<th>Comorbidities</th>
<th>COVID-19 severity</th>
<th>Hospitalisation</th>
<th>COVID-19 Rx</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mihai et al (3)</td>
<td>Case report</td>
<td>Switzerland</td>
<td>n/a</td>
<td>1</td>
<td>57</td>
<td>F</td>
<td>TCZ</td>
<td>u/a</td>
<td>ILD, arthritis</td>
<td>DM, obesity</td>
<td>Mild</td>
<td>No</td>
<td>TCZ</td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Cheng et al (4)</td>
<td>Case report</td>
<td>China</td>
<td>568 COVID-19 hospitalised pts</td>
<td>1</td>
<td>79</td>
<td>M</td>
<td>MTP</td>
<td>u/a</td>
<td>ILD, arthritis</td>
<td>u/a</td>
<td>u/a</td>
<td>COPD</td>
<td>Critical</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Aouac et al (5)</td>
<td>Case series</td>
<td>France/Italy</td>
<td>n/a</td>
<td>1</td>
<td>71</td>
<td>M</td>
<td>PDN, RTX</td>
<td>u/a</td>
<td>cSSc, polyarthritis</td>
<td>RNA pol III, HTN, HLD</td>
<td>Severe</td>
<td>Yes (ICU)</td>
<td>AbX</td>
<td>NIV</td>
<td>R</td>
</tr>
<tr>
<td>Moiseev et al (6)</td>
<td>Retrospective</td>
<td>Russia</td>
<td>902 ICU pts with COVID-19</td>
<td>2</td>
<td>65</td>
<td>F</td>
<td>PDN, RTX</td>
<td>u/a</td>
<td>deSSc, polyarthritis</td>
<td>ILD, GI system, MM</td>
<td>Severe</td>
<td>Yes (ICU)</td>
<td>NIV or IV</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Favalli et al (8)</td>
<td>Survey</td>
<td>Italy</td>
<td>123 pts with CTD</td>
<td>1</td>
<td>32</td>
<td>F</td>
<td>RTX, HCO</td>
<td>u/a</td>
<td>ILD</td>
<td>u/a</td>
<td>u/a</td>
<td>Severe</td>
<td>Yes (ICU)</td>
<td>TCZ</td>
<td>D</td>
</tr>
<tr>
<td>Zen et al (9)</td>
<td>Survey</td>
<td>Italy</td>
<td>916 pts with rheumatic disease, 17b with SSc</td>
<td>1</td>
<td>54</td>
<td>F</td>
<td>MMF</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>(40% of overall cohort hospitalised)</td>
<td>u/a</td>
</tr>
<tr>
<td>Gianfrancesco et al 10)</td>
<td>Registry</td>
<td>40 countries</td>
<td>600 rheumatic pts with COVID-19</td>
<td>16</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
</tr>
<tr>
<td>Pablo et al (7)</td>
<td>Retrospective</td>
<td>Spain</td>
<td>26,131 pts with rheumatic disease</td>
<td>1,14% of those with SSc</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
<td>u/a</td>
</tr>
</tbody>
</table>

AF: atrial fibrillation; autoAb: autoantibodies; ATA: anti-topoisomerase; AZ: azithromycin; CTD: chronic idiopathic disease; COPD: chronic obstructive pulmonary disease; CTD: connective tissue disease; D: death; deSSc: diffuse SSc; DM: diabetes mellitus; GC: glucocorticoids; GI: gastrointestinal; HCO: hydroxychloroquine; HFN: high flow nasal cannula; HLD: hyperlipidaemia; HTN: hypertension; ICU: intensive care unit; IFN: interferon; ILD: interstitial lung disease; IVIg: intravenous immunoglobulins; lSSc: limited SSc; MMF: mycophenolate mofetil; MTP: methylprednisolone; MTX: methotrexate; n/a: not applicable; NIV: non-invasive ventilation; O2: oxygen; PE: pulmonary embolism; pts: patients; PDM: prednisone; R: recovered; RNA pol III: ribonucleic acid polymerase III; RTX: rituximab; Rx: treatment; SSc: systemic sclerosis; TCZ: tocilizumab; u/a: unavailable.
be shared by the two diseases. In some SSc patients, COVID-19 had a fatal outcome. The small number of patients, heterogeneity of data and tendency to report severe cases limit our understanding of how underlying disease or treatment influence prognosis. More robust data gathering derived from the databases (ACR, EULAR, EUSTAR) will allow for a more systematic view of the main signs and symptoms characterizing SARS-CoV-2 infection in SSc. In particular, for the better understanding of the intersection of SSc and COVID-19, the launch of the EUSTAR COVID-19 registry will provide a much more detailed picture.

B. Russo *, MD, PhD
J. Ben Shalom *
M. Matucci-Cerinic *, MD, PhD
C. Bruni *

*Equal contribution as first author.
§Equal contribution as senior author.
1Department of Pathology and Immunology, School of Medicine, University of Geneva, Switzerland;
2Division of Dermatology and Venereology, Geneva University Hospitals, Switzerland;
3Department of Rheumatology, E. Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
4Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Firenze, Italy;
5Department of Geriatric Medicine, Division of Rheumatology AOUC, Firenze, Italy.

Please address correspondence to: Barbara Russo, Centre Médical Universitaire (CMU), Rue Michel-Servet, Genève 1206, Switzerland. E-mail: barbara.russo@unige.ch

(C) Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2020.

Competing interests: M. Matucci Cerinic has received fees for boards from MSD, Biogen, Lilly, Pfizer, BMS, Janssen and Actelion; consultation from Chemomab and grants from MSD. C. Bruni has received consultancy fee from Actelion, Eli Lilly; grants from Gruppo Italiano Lotta alla Scleroderma (GILS), Fondazione Italiana Ricerca sull’Artrite (FIRA), European Scleroderma Trial and Research (EUSTAR), Foundation for Research in Rheumatology (FOREUM), Italian Society for Rheumatology (SIR), outside the submitted work. The other authors declare no competing interests.

References